Logo image of XOMA

XOMA ROYALTY CORPORATION (XOMA) Stock Fundamental Analysis

NASDAQ:XOMA - Nasdaq - US98419J2069 - Common Stock - Currency: USD

25.72  +0.84 (+3.38%)

After market: 25.72 0 (0%)

Fundamental Rating

3

Overall XOMA gets a fundamental rating of 3 out of 10. We evaluated XOMA against 572 industry peers in the Biotechnology industry. XOMA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, XOMA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year XOMA has reported negative net income.
In the past year XOMA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: XOMA reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: XOMA reported negative operating cash flow in multiple years.
XOMA Yearly Net Income VS EBIT VS OCF VS FCFXOMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -18.99%, XOMA is in the better half of the industry, outperforming 78.76% of the companies in the same industry.
XOMA has a Return On Equity of -50.00%. This is in the better half of the industry: XOMA outperforms 66.02% of its industry peers.
Industry RankSector Rank
ROA -18.99%
ROE -50%
ROIC N/A
ROA(3y)-10.35%
ROA(5y)-5.19%
ROE(3y)-21.59%
ROE(5y)-11.77%
ROIC(3y)N/A
ROIC(5y)N/A
XOMA Yearly ROA, ROE, ROICXOMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 400 600 800 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XOMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMA Yearly Profit, Operating, Gross MarginsXOMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

XOMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XOMA has about the same amount of shares outstanding.
XOMA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, XOMA has a worse debt to assets ratio.
XOMA Yearly Shares OutstandingXOMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
XOMA Yearly Total Debt VS Total AssetsXOMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

XOMA has an Altman-Z score of -5.89. This is a bad value and indicates that XOMA is not financially healthy and even has some risk of bankruptcy.
XOMA's Altman-Z score of -5.89 is on the low side compared to the rest of the industry. XOMA is outperformed by 66.02% of its industry peers.
A Debt/Equity ratio of 1.27 is on the high side and indicates that XOMA has dependencies on debt financing.
With a Debt to Equity ratio value of 1.27, XOMA is not doing good in the industry: 80.53% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF N/A
Altman-Z -5.89
ROIC/WACCN/A
WACC10.39%
XOMA Yearly LT Debt VS Equity VS FCFXOMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

XOMA has a Current Ratio of 7.52. This indicates that XOMA is financially healthy and has no problem in meeting its short term obligations.
XOMA's Current ratio of 7.52 is fine compared to the rest of the industry. XOMA outperforms 70.62% of its industry peers.
A Quick Ratio of 7.52 indicates that XOMA has no problem at all paying its short term obligations.
XOMA has a better Quick ratio (7.52) than 70.62% of its industry peers.
Industry RankSector Rank
Current Ratio 7.52
Quick Ratio 7.52
XOMA Yearly Current Assets VS Current LiabilitesXOMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

XOMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.70%, which is quite good.
Looking at the last year, XOMA shows a very strong growth in Revenue. The Revenue has grown by 422.53%.
XOMA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.13% yearly.
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-165%
Revenue 1Y (TTM)422.53%
Revenue growth 3Y-45.5%
Revenue growth 5Y-2.13%
Sales Q2Q%767.11%

3.2 Future

Based on estimates for the next years, XOMA will show a very strong growth in Earnings Per Share. The EPS will grow by 27.50% on average per year.
XOMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 95.48% yearly.
EPS Next Y46.73%
EPS Next 2Y31.88%
EPS Next 3Y27.5%
EPS Next 5YN/A
Revenue Next Year338.75%
Revenue Next 2Y135.98%
Revenue Next 3Y95.48%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
XOMA Yearly Revenue VS EstimatesXOMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M 50M
XOMA Yearly EPS VS EstimatesXOMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XOMA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XOMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XOMA Price Earnings VS Forward Price EarningsXOMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XOMA Per share dataXOMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as XOMA's earnings are expected to grow with 27.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.88%
EPS Next 3Y27.5%

More info and screens

0

5. Dividend

5.1 Amount

XOMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XOMA ROYALTY CORPORATION

NASDAQ:XOMA (2/4/2025, 8:17:09 PM)

After market: 25.72 0 (0%)

25.72

+0.84 (+3.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners66%
Inst Owner Change-0.58%
Ins Owners0.54%
Ins Owner Change-43.84%
Market Cap302.98M
Analysts82.22
Price Target90.78 (252.95%)
Short Float %1.49%
Short Ratio3.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.48
Dividend Growth(5Y)N/A
DP-12.91%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)75.34%
Min EPS beat(2)-256.98%
Max EPS beat(2)407.67%
EPS beat(4)1
Avg EPS beat(4)28.47%
Min EPS beat(4)-256.98%
Max EPS beat(4)407.67%
EPS beat(8)2
Avg EPS beat(8)6.47%
EPS beat(12)3
Avg EPS beat(12)-23.76%
EPS beat(16)4
Avg EPS beat(16)-49.51%
Revenue beat(2)2
Avg Revenue beat(2)19.23%
Min Revenue beat(2)8.67%
Max Revenue beat(2)29.78%
Revenue beat(4)3
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-50.15%
Max Revenue beat(4)29.78%
Revenue beat(8)5
Avg Revenue beat(8)6.7%
Revenue beat(12)6
Avg Revenue beat(12)-9.79%
Revenue beat(16)7
Avg Revenue beat(16)-19.73%
PT rev (1m)0%
PT rev (3m)7.23%
EPS NQ rev (1m)-8.46%
EPS NQ rev (3m)35%
EPS NY rev (1m)0%
EPS NY rev (3m)-840%
Revenue NQ rev (1m)1.2%
Revenue NQ rev (3m)54.86%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)9.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.12
P/FCF N/A
P/OCF N/A
P/B 3.57
P/tB 3.57
EV/EBITDA N/A
EPS(TTM)-2.1
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS1.96
BVpS7.2
TBVpS7.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.99%
ROE -50%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.35%
ROA(5y)-5.19%
ROE(3y)-21.59%
ROE(5y)-11.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.52
Quick Ratio 7.52
Altman-Z -5.89
F-Score5
WACC10.39%
ROIC/WACCN/A
Cap/Depr(3y)4621.84%
Cap/Depr(5y)2783.1%
Cap/Sales(3y)84.42%
Cap/Sales(5y)50.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-165%
EPS Next Y46.73%
EPS Next 2Y31.88%
EPS Next 3Y27.5%
EPS Next 5YN/A
Revenue 1Y (TTM)422.53%
Revenue growth 3Y-45.5%
Revenue growth 5Y-2.13%
Sales Q2Q%767.11%
Revenue Next Year338.75%
Revenue Next 2Y135.98%
Revenue Next 3Y95.48%
Revenue Next 5YN/A
EBIT growth 1Y29.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.29%
EBIT Next 3Y39.43%
EBIT Next 5YN/A
FCF growth 1Y-168.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.24%
OCF growth 3YN/A
OCF growth 5YN/A